{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:18:11Z","timestamp":1793881091277,"version":"4.7.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"NIH","award":["K99 AR082989"],"award-info":[{"award-number":["K99 AR082989"]}]},{"name":"NIH","award":["R01 AR073772"],"award-info":[{"award-number":["R01 AR073772"]}]},{"name":"NIH","award":["P01 CA275740"],"award-info":[{"award-number":["P01 CA275740"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-08693-w","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T23:01:41Z","timestamp":1751410901000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Sexual dimorphism of MASLD-driven bone loss"],"prefix":"10.1038","volume":"15","author":[{"given":"Galen M.","family":"Goldscheitter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mulugeta","family":"Seneshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faridoddin","family":"Mirshahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan G.","family":"Buettmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian C.","family":"Genetos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry J.","family":"Donahue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"8693_CR1","doi-asserted-by":"publisher","unstructured":"Diehl, A. M. & Day, C. \u2018Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis\u2019, New England Journal of Medicine, vol. 377, no. 21, pp. 2063\u20132072, Nov. (2017). https:\/\/doi.org\/10.1056\/NEJMra1503519","DOI":"10.1056\/NEJMra1503519"},{"key":"8693_CR2","unstructured":"Chen, H. J. et al. \u2018Increased risk of osteoporosis in patients with nonalcoholic fatty liver disease: A population-based retrospective cohort study\u2019, Medicine, vol. 97, no. 42, [Online]. (2018). Available: https:\/\/journals.lww.com\/md-journal\/Fulltext\/2018\/10190\/Increased_risk_of_osteoporosis_in_patients_with.48.aspx"},{"key":"8693_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4862","author":"YH Su","year":"2023","unstructured":"Su, Y. H. et al. Nonalcoholic fatty liver disease is associated with decreased bone mineral density in adults: A systematic review and Meta-Analysis. J. Bone Min. Res. https:\/\/doi.org\/10.1002\/jbmr.4862 (2023).","journal-title":"J. Bone Min. Res."},{"issue":"11","key":"8693_CR4","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1007\/s00198-022-06459-y","volume":"33","author":"B Pan","year":"2022","unstructured":"Pan, B. et al. Relationship between prevalence and risk of osteoporosis or osteoporotic fracture with non-alcoholic fatty liver disease: A systematic review and meta-analysis. Osteoporos. Int. 33 (11), 2275\u20132286. https:\/\/doi.org\/10.1007\/s00198-022-06459-y (2022).","journal-title":"Osteoporos. Int."},{"key":"8693_CR5","doi-asserted-by":"publisher","first-page":"1215790","DOI":"10.3389\/fendo.2023.1215790","volume":"14","author":"A Cui","year":"2023","unstructured":"Cui, A. et al. Causal association of NAFLD with osteoporosis, fracture and falling risk: a bidirectional Mendelian randomization study. Front. Endocrinol. (Lausanne). 14, 1215790. https:\/\/doi.org\/10.3389\/fendo.2023.1215790 (2023).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"8693_CR6","doi-asserted-by":"publisher","unstructured":"Pei, X. et al. Mendelian-randomization study revealed causal relationship between nonalcoholic fatty liver disease and osteoporosis\/fractures. J. Gastroenterol. Hepatol. https:\/\/doi.org\/10.1111\/jgh.16448 (Jan. 2024).","DOI":"10.1111\/jgh.16448"},{"key":"8693_CR7","doi-asserted-by":"publisher","first-page":"1161402","DOI":"10.3389\/fendo.2023.1161402","volume":"14","author":"J Zhao","year":"2023","unstructured":"Zhao, J., Lei, H., Wang, T. & Xiong, X. Liver-bone crosstalk in non-alcoholic fatty liver disease: clinical implications and underlying pathophysiology. Front. Endocrinol. (Lausanne). 14, 1161402. https:\/\/doi.org\/10.3389\/fendo.2023.1161402 (2023).","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"8","key":"8693_CR8","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3748\/wjg.v18.i8.727","volume":"18","author":"V Braunersreuther","year":"2012","unstructured":"Braunersreuther, V., Viviani, G. L., Mach, F. & Montecucco, F. Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J. Gastroenterol. 18 (8), 727\u2013735. https:\/\/doi.org\/10.3748\/wjg.v18.i8.727 (2012).","journal-title":"World J. Gastroenterol."},{"key":"8693_CR9","doi-asserted-by":"publisher","unstructured":"Duan, Y. et al. Association of inflammatory cytokines with Non-Alcoholic fatty liver disease. Front. Immunol. 13 https:\/\/doi.org\/10.3389\/FIMMU.2022.880298 (May 2022).","DOI":"10.3389\/FIMMU.2022.880298"},{"key":"8693_CR10","doi-asserted-by":"publisher","unstructured":"Lu, N. et al. Jan., \u2018RANKL Is Independently Associated with Increased Risks of Non-Alcoholic Fatty Liver Disease in Chinese Women with PCOS: A Cross-Sectional Study\u2019, J Clin Med, vol. 12, no. 2, (2023). https:\/\/doi.org\/10.3390\/JCM12020451","DOI":"10.3390\/JCM12020451"},{"issue":"9","key":"8693_CR11","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1111\/dom.14774","volume":"24","author":"ID Vachliotis","year":"2022","unstructured":"Vachliotis, I. D., Anastasilakis, A. D., Goulas, A., Goulis, D. G. & Polyzos, S. A. Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implications. Diabetes Obes. Metab. 24 (9), 1702\u20131720. https:\/\/doi.org\/10.1111\/dom.14774 (2022).","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"8693_CR12","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12902-016-0148-0","volume":"16","author":"A Takeno","year":"2016","unstructured":"Takeno, A., Yamamoto, M., Notsu, M. & Sugimoto, T. Administration of anti-receptor activator of nuclear factor-kappa B ligand (RANKL) antibody for the treatment of osteoporosis was associated with amelioration of hepatitis in a female patient with growth hormone deficiency: a case report. BMC Endocr. Disord. 16 (1), 66. https:\/\/doi.org\/10.1186\/s12902-016-0148-0 (2016).","journal-title":"BMC Endocr. Disord"},{"issue":"3","key":"8693_CR13","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nm.3084","volume":"19","author":"S Kiechl","year":"2013","unstructured":"Kiechl, S. et al. Blockade of receptor activator of nuclear factor-\u03baB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat. Med. 19 (3), 358\u2013363. https:\/\/doi.org\/10.1038\/nm.3084 (2013).","journal-title":"Nat. Med."},{"key":"8693_CR14","doi-asserted-by":"publisher","unstructured":"Lyu, H. et al. Oct., \u2018Delayed Denosumab Injections and Fracture Risk Among Patients With Osteoporosis: A Population-Based Cohort Study\u2019, Ann Intern Med, vol. 173, no. 7, pp. 516\u2013526, (2020). https:\/\/doi.org\/10.7326\/M20-0882","DOI":"10.7326\/M20-0882"},{"key":"8693_CR15","doi-asserted-by":"publisher","unstructured":"Asgharpour, A. et al. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. J. Hepatol. 65 (3), 579\u2013588. https:\/\/doi.org\/10.1016\/j.jhep.2016.05.005 (Sep. 2016).","DOI":"10.1016\/j.jhep.2016.05.005"},{"key":"8693_CR16","doi-asserted-by":"publisher","unstructured":"Vacca, M. et al. Jun., \u2018An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)\u2019, Nature Metabolism 2024 6:6, vol. 6, no. 6, pp. 1178\u20131196, (2024). https:\/\/doi.org\/10.1038\/s42255-024-01043-6","DOI":"10.1038\/s42255-024-01043-6"},{"key":"8693_CR17","doi-asserted-by":"publisher","unstructured":"Banini, B. A. et al. Apr., \u2018Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin-Like Phospholipase Domain Containing 3-Mediated Acceleration of Steatohepatitis\u2019, Hepatology, vol. 73, no. 4, pp. 1290\u20131306, (2021). https:\/\/doi.org\/10.1002\/HEP.31609","DOI":"10.1002\/HEP.31609"},{"issue":"1","key":"8693_CR18","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/s41598-022-05228-5","volume":"12","author":"S Nucera","year":"2022","unstructured":"Nucera, S. et al. MAFLD progression contributes to altered thalamus metabolism and brain structure. Sci. Rep. 12 (1), 1207. https:\/\/doi.org\/10.1038\/s41598-022-05228-5 (2022).","journal-title":"Sci. Rep."},{"key":"8693_CR19","doi-asserted-by":"publisher","unstructured":"Notelovitz, M. \u2018Androgen effects on bone and muscle.\u2019, Fertil Steril, vol. 77 Suppl 4, pp. S34-41, Apr. (2002). https:\/\/doi.org\/10.1016\/s0015-0282(02)02968-0","DOI":"10.1016\/s0015-0282(02)02968-0"},{"key":"8693_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17082620","author":"P Kur","year":"2020","unstructured":"Kur, P., Kolasa-Wo\u0142osiuk, A., Misiakiewicz-Has, K. & Wiszniewska, B. Sex hormone-dependent physiology and diseases of liver\u2019, apr. 02. MDPI AG. https:\/\/doi.org\/10.3390\/ijerph17082620 (2020).","journal-title":"MDPI AG"},{"key":"8693_CR21","doi-asserted-by":"publisher","unstructured":"Moon, S. S., Lee, Y. S. & Kim, S. W. \u2018Association of nonalcoholic fatty liver disease with low bone mass in postmenopausal women\u2019, Endocrine, vol. 42, no. 2, pp. 423\u2013429, (2012). https:\/\/doi.org\/10.1007\/s12020-012-9639-6","DOI":"10.1007\/s12020-012-9639-6"},{"key":"8693_CR22","doi-asserted-by":"publisher","unstructured":"Xia, M. F. et al. The association of liver fat content and serum Alanine aminotransferase with bone mineral density in middle-aged and elderly Chinese men and postmenopausal women. J. Transl Med. 14 (1, p. 11, ). https:\/\/doi.org\/10.1186\/s12967-016-0766-3 (2016).","DOI":"10.1186\/s12967-016-0766-3"},{"key":"8693_CR23","doi-asserted-by":"publisher","unstructured":"Kameda, T. et al. Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. J. Exp. Med. 186 (4), 489\u2013495. https:\/\/doi.org\/10.1084\/JEM.186.4.489 (Aug. 1997).","DOI":"10.1084\/JEM.186.4.489"},{"key":"8693_CR24","doi-asserted-by":"publisher","unstructured":"Li, X. et al. Nov., \u2018Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis\u2019, J Biol Chem, vol. 282, no. 45, pp. 33086\u201333097, (2007). https:\/\/doi.org\/10.1074\/JBC.M705194200","DOI":"10.1074\/JBC.M705194200"},{"key":"8693_CR25","doi-asserted-by":"publisher","unstructured":"Browaeys, R., Saelens, W. & Saeys, Y. \u2018NicheNet: modeling intercellular communication by linking ligands to target genes\u2019, Nature Methods 2019 17:2, vol. 17, no. 2, pp. 159\u2013162, Dec. (2019). https:\/\/doi.org\/10.1038\/s41592-019-0667-5","DOI":"10.1038\/s41592-019-0667-5"},{"key":"8693_CR26","doi-asserted-by":"publisher","unstructured":"Halloran, B. P. et al. \u2018Changes in bone structure and mass with advancing age in the male C57BL\/6J mouse.\u2019, J Bone Miner Res, vol. 17, no. 6, pp. 1044\u20131050, Jun. (2002). https:\/\/doi.org\/10.1359\/jbmr.2002.17.6.1044","DOI":"10.1359\/jbmr.2002.17.6.1044"},{"key":"8693_CR27","doi-asserted-by":"publisher","unstructured":"Ji, X. et al. \u2018Genetic activation of glycolysis in osteoblasts preserves bone mass in type I diabetes\u2019, Cell Chem Biol, vol. 30, no. 9, pp. 1053\u20131063.e5, 2023. https:\/\/doi.org\/10.1016\/j.chembiol.2023.07.003","DOI":"10.1016\/j.chembiol.2023.07.003"},{"key":"8693_CR28","doi-asserted-by":"publisher","unstructured":"Carvalho, F. R. et al. Jun., \u2018Altered bone microarchitecture in a type 1 diabetes mouse model Ins2\u2019, J Cell Physiol, vol. 234, no. 6, pp. 9338\u20139350, (2019). https:\/\/doi.org\/10.1002\/jcp.27617","DOI":"10.1002\/jcp.27617"},{"key":"8693_CR29","doi-asserted-by":"publisher","unstructured":"Nilsson, M. E. et al. Jul., \u2018Measurement of a Comprehensive Sex Steroid Profile in Rodent Serum by High-Sensitive Gas Chromatography-Tandem Mass Spectrometry\u2019, Endocrinology, vol. 156, no. 7, pp. 2492\u20132502, (2015). https:\/\/doi.org\/10.1210\/EN.2014-1890","DOI":"10.1210\/EN.2014-1890"},{"key":"8693_CR30","doi-asserted-by":"publisher","unstructured":"Canalis, E., Zanotti, S., Beamer, W. G., Economides, A. N. & Smerdel-Ramoya, A. \u2018Connective tissue growth factor is required for skeletal development and postnatal skeletal homeostasis in male mice\u2019, Endocrinology, vol. 151, no. 8, pp. 3490\u20133501, Aug. (2010). https:\/\/doi.org\/10.1210\/EN.2010-0145","DOI":"10.1210\/EN.2010-0145"},{"key":"8693_CR31","doi-asserted-by":"publisher","unstructured":"Smerdel-Ramoya, A., Zanotti, S., Stadmeyer, L., Durant, D. & Canalis, E. \u2018Skeletal overexpression of connective tissue growth factor impairs bone formation and causes osteopenia\u2019, Endocrinology, vol. 149, no. 9, pp. 4374\u20134381, Sep. (2008). https:\/\/doi.org\/10.1210\/EN.2008-0254","DOI":"10.1210\/EN.2008-0254"},{"key":"8693_CR32","doi-asserted-by":"publisher","unstructured":"Kadric, L. et al. \u2018Associations Between Plasma Chemerin Concentrations and Bone Quality in Adults From the General Population\u2019, Endocrinology, vol. 159, no. 6, pp. 2378\u20132385, Jun. (2018). https:\/\/doi.org\/10.1210\/EN.2018-00157","DOI":"10.1210\/EN.2018-00157"},{"key":"8693_CR33","doi-asserted-by":"publisher","unstructured":"Ramos-Junior, E. S. et al. Adipokine chemerin bridges metabolic dyslipidemia and alveolar bone loss in mice. J. Bone Min. Res. 32 (5), 974\u2013984. https:\/\/doi.org\/10.1002\/JBMR.3072 (May 2017).","DOI":"10.1002\/JBMR.3072"},{"key":"8693_CR34","doi-asserted-by":"publisher","unstructured":"Han, L. et al. Loss of chemerin triggers bone remodeling in vivo and in vitro. Mol. Metab. 53 https:\/\/doi.org\/10.1016\/J.MOLMET.2021.101322 (Nov. 2021).","DOI":"10.1016\/J.MOLMET.2021.101322"},{"key":"8693_CR35","doi-asserted-by":"publisher","unstructured":"Ren, Q. et al. Circulating chemerin levels in metabolic-associated fatty liver disease: a systematic review and meta-analysis. Lipids Health Dis. 21 (1). https:\/\/doi.org\/10.1186\/S12944-022-01637-7 (Dec. 2022).","DOI":"10.1186\/S12944-022-01637-7"},{"key":"8693_CR36","doi-asserted-by":"publisher","unstructured":"Krautbauer, S. et al. Oct., \u2018Chemerin is highly expressed in hepatocytes and is induced in non-alcoholic steatohepatitis liver\u2019, Exp Mol Pathol, vol. 95, no. 2, pp. 199\u2013205, (2013). https:\/\/doi.org\/10.1016\/J.YEXMP.2013.07.009","DOI":"10.1016\/J.YEXMP.2013.07.009"},{"key":"8693_CR37","doi-asserted-by":"publisher","unstructured":"Hopwood, B., Tsykin, A., Findlay, D. M. & Fazzalari, N. L. \u2018Gene expression profile of the bone microenvironment in human fragility fracture bone\u2019, Bone, vol. 44, no. 1, pp. 87\u2013101, Jan. (2009). https:\/\/doi.org\/10.1016\/J.BONE.2008.08.120","DOI":"10.1016\/J.BONE.2008.08.120"},{"key":"8693_CR38","doi-asserted-by":"publisher","unstructured":"Zhou, X. et al. Anxa2 attenuates osteoblast growth and is associated with hip BMD and osteoporotic fracture in Chinese elderly. PLoS One. 13 (3). https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0194781 (Mar. 2018).","DOI":"10.1371\/JOURNAL.PONE.0194781"},{"key":"8693_CR39","doi-asserted-by":"publisher","unstructured":"Li, F. et al. Jul., \u2018Annexin II stimulates RANKL expression through MAPK\u2019, J Bone Miner Res, vol. 20, no. 7, pp. 1161\u20131167, (2005). https:\/\/doi.org\/10.1359\/JBMR.050207","DOI":"10.1359\/JBMR.050207"},{"key":"8693_CR40","doi-asserted-by":"publisher","unstructured":"Berglund, E. D. et al. Sep., \u2018Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity\u2019, Endocrinology, vol. 150, no. 9, pp. 4084\u20134093, (2009). https:\/\/doi.org\/10.1210\/EN.2009-0221","DOI":"10.1210\/EN.2009-0221"},{"key":"8693_CR41","doi-asserted-by":"publisher","unstructured":"Kharitonenkov, A. et al. Jun., \u2018FGF-21 as a novel metabolic regulator\u2019, J Clin Invest, vol. 115, no. 6, pp. 1627\u20131635, (2005). https:\/\/doi.org\/10.1172\/JCI23606","DOI":"10.1172\/JCI23606"},{"key":"8693_CR42","doi-asserted-by":"publisher","unstructured":"Coskun, T. et al. Dec., \u2018Fibroblast growth factor 21 corrects obesity in mice\u2019, Endocrinology, vol. 149, no. 12, pp. 6018\u20136027, (2008). https:\/\/doi.org\/10.1210\/EN.2008-0816","DOI":"10.1210\/EN.2008-0816"},{"key":"8693_CR43","doi-asserted-by":"publisher","unstructured":"Wei, W. et al. Feb., \u2018Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor \u03b3\u2019, Proc Natl Acad Sci U S A, vol. 109, no. 8, pp. 3143\u20133148, (2012). https:\/\/doi.org\/10.1073\/PNAS.1200797109","DOI":"10.1073\/PNAS.1200797109"},{"key":"8693_CR44","doi-asserted-by":"publisher","unstructured":"Wang, M. et al. MMP13 is a critical target gene during the progression of osteoarthritis. Arthritis Res. Ther. 15 (1). https:\/\/doi.org\/10.1186\/AR4133 (Jan. 2013).","DOI":"10.1186\/AR4133"},{"key":"8693_CR45","doi-asserted-by":"publisher","unstructured":"Pivetta, E. et al. MMP-13 stimulates osteoclast differentiation and activation in tumour breast bone metastases. Breast Cancer Res. 13 (5). https:\/\/doi.org\/10.1186\/BCR3047 (Oct. 2011).","DOI":"10.1186\/BCR3047"},{"key":"8693_CR46","doi-asserted-by":"publisher","unstructured":"Ponte, F. et al. Mmp13 deletion in mesenchymal cells increases bone mass and May attenuate the cortical bone loss caused by Estrogen deficiency. Sci. Rep. 12 (1). https:\/\/doi.org\/10.1038\/S41598-022-14470-W (Dec. 2022).","DOI":"10.1038\/S41598-022-14470-W"},{"key":"8693_CR47","doi-asserted-by":"publisher","unstructured":"Bouxsein, M. L. et al. \u2018Guidelines for assessment of bone microstructure in rodents using micro-computed tomography\u2019, J Bone Miner Res, vol. 25, no. 7, pp. 1468\u20131486, Jul. (2010). https:\/\/doi.org\/10.1002\/JBMR.141","DOI":"10.1002\/JBMR.141"},{"key":"8693_CR48","doi-asserted-by":"publisher","first-page":"111414","DOI":"10.1016\/j.jbiomech.2022.111414","volume":"146","author":"RC DeNapoli","year":"2022","unstructured":"DeNapoli, R. C., Buettmann, E. G., Friedman, M. A., Lichtman, A. H. & Donahue, H. J. Global cannabinoid receptor 1 deficiency affects disuse-induced bone loss in a site-specific and sex-dependent manner. J. Biomech. 146, 111414. https:\/\/doi.org\/10.1016\/j.jbiomech.2022.111414 (2022).","journal-title":"J. Biomech."},{"key":"8693_CR49","doi-asserted-by":"publisher","unstructured":"Friedman, M. A., Zhang, Y., Wayne, J. S., Farber, C. R. & Donahue, H. J. Single limb immobilization model for bone loss from unloading. J. Biomech. 83, 181\u2013189. https:\/\/doi.org\/10.1016\/j.jbiomech.2018.11.049 (Jan. 2019).","DOI":"10.1016\/j.jbiomech.2018.11.049"},{"key":"8693_CR50","doi-asserted-by":"publisher","unstructured":"Jepsen, K. J., Silva, M. J., Vashishth, D., Guo, X. E. & Van Der Meulen, M. C. H. \u2018Establishing biomechanical mechanisms in mouse models: practical guidelines for systematically evaluating phenotypic changes in the diaphyses of long bones\u2019, J Bone Miner Res, vol. 30, no. 6, pp. 951\u2013966, Jun. (2015). https:\/\/doi.org\/10.1002\/JBMR.2539","DOI":"10.1002\/JBMR.2539"},{"key":"8693_CR51","doi-asserted-by":"publisher","unstructured":"Cherief, M. et al. TrkA-mediated sensory innervation of injured mouse tendon supports tendon sheath progenitor cell expansion and tendon repair. Sci. Transl Med. 15, 727. https:\/\/doi.org\/10.1126\/scitranslmed.ade4619 (2023).","DOI":"10.1126\/scitranslmed.ade4619"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-08693-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-08693-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-08693-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T11:02:15Z","timestamp":1751799735000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-08693-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8693"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-08693-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.11.25.625246","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"26 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AJS owns stock or equity in Durect, Genfit, Sanyal Bio, and Tiziana. He receives research support from AstraZeneca, Avant Sante, Boehringer Ingelheim, Bristol Meyers, Intercept, Lilly, Madrigal, Novartis, Novo Nordisk, and Pfizer. He serves as a consultant to 89 Bio, Alnylam, AstraZeneca, BiocellVia, Boehringer Ingelheim, Fibronest, Fractyl, Genentech, GlaxoSmithKline, HistoIndex, Intercept, Madrigal, Merck, NGM Bio, NorthSea, Novartis, Novo Nordisk, PathAI, Pfizer, Regeneron, Roche, Takeda, Target PharmaSolutions, and Terns. The remaining authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23090"}}